Back

Clinical application of the HFA/ICOS score in breast cancer women: its added value in the prediction of chemotherapy-related cardiac dysfunction

26 August 2023 (16:15 - 16:50)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk in patients with cancer Cardio-Oncology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Giuseppina Novo

University of Palermo, Palermo (Italy)

5 More presentations in this session

Presentation thumbnail
Association between fasting glucose and cardiovascular disease mortality in cancer survivors: a population-based study
Doctor M. Jung (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Anti-diabetic medication adherence and cardiovascular outcomes in patients with cancer: a nationwide population-based cohort study
Doctor M. Jung (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Is staging for cardiac damage in aortic stenosis associated with MACE in cancer patients with prior radiotherapy or chemotherapy that underwent transcatheter aortic valve replacement?
Doctor S. Santos Patarroyo (Rochester, US)
Abstract Slides Video
Presentation thumbnail
The Dutch Cardio-Oncology cohort: Incidence of cardiovascular disease predisposes to a higher cancer mortality rate.
Assistant Professor Y. Koop (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Cardiac CARE study: How the ESC Cardio-Oncology guidelines fo 2022 affect the study population
Doctor K. Loganath (Southampton, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular risk in patients with cancer

The Event

Event poster

ESC Congress 2023

26 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
A study to assess the ability of the HFA-ICOS risk stratification tool to predict cancer therapy-related cardiac dysfunction for patients receiving anthracycline chemotherapy.
thumbnail
Congress Presentation
Cardiotoxicity risk assessment using HFA-ICOS score: a cross-sectional analysis of patients with breast cancer undergoing chemotherapy or anti-HER2 therapies in a tertiary care center

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources